← Back to Search

Beta-3 Adrenergic Agonist

Cohort A Vibegron for Overactive Bladder

N/A
Waitlist Available
Research Sponsored by Urovant Sciences GmbH
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 6
Awards & highlights
No Placebo-Only Group

Summary

This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice.

Eligible Conditions
  • Overactive Bladder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 6 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean Satisfaction Domain Score as Assessed by the OAB-SAT-q
Mean Satisfaction Domain Score as Assessed by the Overactive Bladder Satisfaction with Treatment Questionnaire (OAB-SAT-q)

Side effects data

From 2022 Phase 3 trial • 276 Patients • NCT04103450
2%
COVID-19
1%
Cervical vertebral fracture
1%
Atrial fibrillation
1%
Non-cardiac chest pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
28-Week Vibegron Group
52-Week Vibegron Group

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort B VibegronExperimental Treatment1 Intervention
Participants with previous mirabegron monotherapy or mirabegron plus solifenacin or combination therapy experience will receive vibegron as per the U.S. label.
Group II: Cohort A VibegronExperimental Treatment1 Intervention
Participants with previous anticholinergic therapy experience will receive vibegron as per the United States (U.S.) label.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vibegron
2018
Completed Phase 3
~3520

Find a Location

Who is running the clinical trial?

Urovant Sciences GmbHLead Sponsor
10 Previous Clinical Trials
3,864 Total Patients Enrolled
Study DirectorStudy DirectorUrovant Sciences
1,276 Previous Clinical Trials
498,877 Total Patients Enrolled
~100 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top